These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 26695547)

  • 1. Novel strategies to target the ubiquitin proteasome system in multiple myeloma.
    Lub S; Maes K; Menu E; De Bruyne E; Vanderkerken K; Van Valckenborgh E
    Oncotarget; 2016 Feb; 7(6):6521-37. PubMed ID: 26695547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A patent review of the ubiquitin ligase system: 2015-2018.
    Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
    Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
    Crosas B
    Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapies targeting the ubiquitin proteasome system in cancer.
    Weathington NM; Mallampalli RK
    J Clin Invest; 2014 Jan; 124(1):6-12. PubMed ID: 24382383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy.
    Goru SK; Kadakol A; Gaikwad AB
    Pharmacol Res; 2017 Jun; 120():170-179. PubMed ID: 28363724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.
    Micel LN; Tentler JJ; Smith PG; Eckhardt GS
    J Clin Oncol; 2013 Mar; 31(9):1231-8. PubMed ID: 23358974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
    Park J; Cho J; Song EJ
    Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Dou QP; Zonder JA
    Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cullin-RING Ligases as attractive anti-cancer targets.
    Zhao Y; Sun Y
    Curr Pharm Des; 2013; 19(18):3215-25. PubMed ID: 23151137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
    Landré V; Rotblat B; Melino S; Bernassola F; Melino G
    Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
    Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
    Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitination and deubiquitination: Implications on cancer therapy.
    Dagar G; Kumar R; Yadav KK; Singh M; Pandita TK
    Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194979. PubMed ID: 37633647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the ubiquitin pathway for cancer treatment.
    Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W
    Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on natural products for drug development].
    Tsukamoto S
    Yakugaku Zasshi; 2010 Oct; 130(10):1273-81. PubMed ID: 20930478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting E3 ubiquitin ligases for cancer therapy.
    Sun Y
    Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the ubiquitin proteasome system in hematologic malignancies.
    Sahasrabuddhe AA; Elenitoba-Johnson KS
    Immunol Rev; 2015 Jan; 263(1):224-39. PubMed ID: 25510280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
    Driscoll JJ; Dechowdhury R
    Target Oncol; 2010 Dec; 5(4):281-9. PubMed ID: 21125340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
    Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
    Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.
    Liu F; Chen J; Li K; Li H; Zhu Y; Zhai Y; Lu B; Fan Y; Liu Z; Chen X; Jia X; Dong Z; Liu K
    Mol Cancer; 2024 Jul; 23(1):148. PubMed ID: 39048965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
    Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP
    Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.